Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6

Not really. That 5.5 million or so will be burnt through very quickly with a multi-country trial and possibly looking to commence a separate trial in the US. Spend was at roughly 2m in the previous quarter and it won't be lower than that going forward. 2-3 quarters left. Im sure they'll start dangling the 'partnerships' carrot soon like every other Aussie biotech, and it'll likely amount to nothing like every other biotech! Some mid-way efficacy and a raise at slightly higher prices I assume is what they're trying to hang on for.. Unsure if that'll be feasible.